

Accepted Manuscript

Title: Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as GVHD Prophylaxis

Author: Austin P. Huffman, Lee P. Richman, Lisa Crisalli, Alex Ganetsky, David L. Porter, Robert H. Vonderheide, Ran Reshef

PII: S1083-8791(17)30797-8

DOI: <https://doi.org/doi:10.1016/j.bbmt.2017.10.028>

Reference: YBBMT 54842


To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 26-7-2017

Accepted date: 15-10-2017

Please cite this article as: Austin P. Huffman, Lee P. Richman, Lisa Crisalli, Alex Ganetsky, David L. Porter, Robert H. Vonderheide, Ran Reshef, Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as GVHD Prophylaxis, *Biology of Blood and Marrow Transplantation* (2017), <https://doi.org/doi:10.1016/j.bbmt.2017.10.028>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Title: Pharmacodynamic monitoring predicts outcomes of CCR5 blockade as GVHD prophylaxis

Authors: Austin P. Huffman, BA^{1,2}, Lee P. Richman, BS^{1,3}, Lisa Crisalli, BS¹, Alex Ganetsky, PharmD¹, David L. Porter, MD¹, Robert H. Vonderheide, MD, D Phil^{1,3} and Ran Reshef, MD^{1,2*}

Affiliations:

¹Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104

²Division of Hematology/Oncology and the Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY 10032

³Abramson Family Cancer Research Institute, Philadelphia, PA 19104

Funding sources: Amy Strelzer Manasevit Award from the National Marrow Donor Program; Career Development Award from the Conquer Cancer Foundation; National Institutes of Health grants P30-CA16520, K23-CA178202 & U01-HL069286. Pfizer supplied maraviroc for the clinical trial described in this manuscript.

*To whom correspondence should be addressed: Ran Reshef, Division of Hematology/Oncology and the Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, 630 W. 168th St., Mailbox 127, New York, NY 10032; email: ran.reshef@columbia.edu; phone: (212) 342-0530; fax: (212) 342-0550

Short Title: Pharmacodynamic monitoring of CCR5 blockade

Download English Version:

<https://daneshyari.com/en/article/8430136>

Download Persian Version:

<https://daneshyari.com/article/8430136>

[Daneshyari.com](https://daneshyari.com)